What is the drug development landscape for Brain drugs?

This quote from Julia Skripka-Serry, BSc, MSc writing in BrainBlogger is instructive. 

Is Big Pharma shying away from CNS drugs?
Because the brain remains so poorly understood, Big Pharma are having a bad time developing pharmaceuticals which act upon the central nervous system (CNS). After a number of very loud and painful CNS clinical trial failures in recent years, GSK, AstraZeneca and Novartis have announced total closures of neuroscience divisions globally. Meanwhile Pfizer, Sanofi, Janssen and Merck have begun to significantly downsize CNS operations.
Few remain in the race. And who can blame them, when CNS drug development can cost billions more than any other therapeutic area, yet has a 45% higher chance of failure than drugs targeting other disorders?

With this as the landscape the only hope I can see is for a great stroke association to take charge, plan out a strategy and solicit funds to hire researchers to solve those specific problems identified in the strategy. 
Notably like:
the Michael J. Fox Foundation
Myelin Repair and the
Alzheimers Association 
I could easily see shilling for donors, asking if they want to donate to the stem cell line of research, or the glutamate poisoning line, or the excitotoxicity line, or their own choice(naming rights available).
Or do they want to support the boring press release line, - F.A.S.T, eat healthy, exercise, prevention, etc.

The existing focus of the ASA, NSA and WSO is not enough to solve any of the problems in stroke. New thinking is required and I doubt that will come from any of them.